BioPharma DiveOriginal article
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
Data ReadoutpositivePositive
AI Analysis
Summary
Roivant reported exceptional results in its pulmonary hypertension drug with analyst projections of $10 billion-plus peak sales. Bristol Myers showcased a first-of-its-kind CAR-T therapy while AstraZeneca advanced despite a previous negative advisory committee vote and Pharvaris achieved success in a key study.
Outcome Details
Roivant reported exceptional results in pulmonary hypertension drug; Pharvaris claimed success in key study; AstraZeneca overcame negative advisory committee vote
Importance:7/10
Sentiment:
0.75
pulmonary_hypertensionCAR-T_therapyclinical_dataadvisory_committeefirst-of-its-kind
Read the original article
Published by BioPharma Dive on September 8, 2026 6:41 PM